Viatris Inc vs Teucrium Wheat Fund — how do they compare? Viatris Inc trades at $16.28 (market cap $18.69B), while Teucrium Wheat Fund trades at $24.49. The key difference: Viatris Inc pays a 2.95% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals.
| VTRS | WEAT | |
|---|---|---|
Market Cap | $18.69B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $17.86 | $26.00 |
52-Week Low | $9.49 | $19.88 |
Enterprise Value | $30.80B | — |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
WEAT (Teucrium Wheat Fund) trades at $24.36, up 1.46% over the past day, with a bullish technical signal driven by moving averages. Recent performance includes a 9.9% gain over the past month and a 25% year-to-date increase as of Zacks Investment Research on July 21, 2026. The USDA reduced its 2026 U.S. wheat production outlook to 1.56 billion bushels on May 12, 2026, influencing commodity-driven volatility.
The outlook remains positive due to strong momentum and inflation hedging appeal, but risks include agricultural supply shocks and macroeconomic pressures. Investors should weigh the fund's exposure to wheat price swings against potential for continued commodity strength amid ongoing inflation concerns highlighted by ETF Trends as of June 2026.
Trailing returns across standard periods
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →